---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Incidence"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Incidence. Topics: United States, 2023: kidney failure by race in the US Renal Data System; Registry data: no AMKD diagnosis in the US Renal Data System; Fraction of disease attributable to the high-risk genotype; Penetrance: lifetime risk of CKD, kidney failure, FSGS, and HIVAN among genotype carriers; 5 further topics. 9 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/incidence"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Incidence

<a id="heading-2.2.1.2.1"></a>

## 2.2.1.2.1 Incidence of APOL1-mediated kidney disease

<a id="topic-2.2.1.2.1-1"></a>

### United States, 2023: kidney failure by race in the US Renal Data System

> “Racial disparities persist: Kidney failure was over four times more common among Black people and twice as common among Hispanic people compared with White people in 2023.”

Source: [USRDS Annual Data Report, ESKD incidence and prevalence (2025)](https://usrds-adr.niddk.nih.gov/2025/end-stage-renal-disease/1-incidence-and-prevalence)

> “ESKD affects approximately 750,000 people in the United States and represents a major health disparity, with incidence approximately three-fold higher among Black people than among White people.”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

> “According to the United States Renal Data System 2020 Annual Data Report, 30% of patients with end-stage kidney disease (ESKD) in the US are Black individuals, although they comprise only 13% to 14% of the population.”

Source: [Hopper and Olabisi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11462457/)

<a id="topic-2.2.1.2.1-2"></a>

### Registry data: no AMKD diagnosis in the US Renal Data System

> “The lack of an AMKD diagnosis in the US Renal Data System and international registries has had profound effects on public health, confusing the epidemiology of kidney failure and delaying research for more accurate diagnoses and treatments.”

Source: [Freedman et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41577386/)

<a id="topic-2.2.1.2.1-3"></a>

### Fraction of disease attributable to the high-risk genotype

> “Rates of many types of severe kidney disease are much higher in Black individuals than most other ethnic groups. Much of this disparity can now be attributed to genetic variants in the apoL1 (APOL1) gene found only in individuals with recent African ancestry.”

Source: [Friedman and Pollak (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7863644/)

> “The effect of carrying two APOL1 risk alleles explains 18% of FSGS and 35% of HIVAN; alternatively, eliminating this effect would reduce FSGS and HIVAN by 67%.”

Source: [Kopp et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3231787/)

> “indicating that APOL1 genotype alone does not account for the entirety of the excess incidence of CKD in the Black community.”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

<a id="topic-2.2.1.2.1-4"></a>

### Penetrance: lifetime risk of CKD, kidney failure, FSGS, and HIVAN among genotype carriers

> “Studies in African American individuals indicate that approximately 15%–20% of individuals with 2 APOL1 risk alleles develop CKD”
> “Approximately 15% of individuals with an APOL1 high-risk genotype will develop kidney failure, and a smaller fraction will develop FSGS.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “Individuals with a high-risk APOL1 genotype have been estimated to have a 15% to 30% lifetime risk of developing ESKD.”
> “The basis of this variable penetrance is currently unknown.”

Source: [Hopper and Olabisi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11462457/)

> “The lifetime risk of clinically significant kidney disease for individuals with two APOL1 risk alleles remains uncertain.”
> “Some estimates pose that the lifetime probability of developing ESKD for carriers of the high-risk genotype may be up to 15%, a number that requires refinement (51).”

Source: [Friedman and Pollak (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7863644/)

> “Individuals with two APOL1 risk alleles have an estimated 4% lifetime risk for developing FSGS, and untreated HIV-infected individuals have a 50% risk for developing HIVAN.”

Source: [Kopp et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3231787/)

<a id="topic-2.2.1.2.1-5"></a>

### Atherosclerosis Risk in Communities study: incident CKD and ESKD in middle-aged Black adults

> “Carrying two risk alleles associated with a 1.49-fold increased risk of CKD (95% CI=1.02 to 2.17) and a 1.88-fold increased risk of ESRD (95% CI=1.20 to 2.93) compared with zero or one risk allele; associations persisted after adjusting for European ancestry.”
> “Among 3067 African-American participants free of CKD at baseline, 190 (6.2%) participants developed CKD. The overall incidence rate of CKD was 7.94 events/1000 person-years among participants carrying zero APOL1 risk alleles, 8.60 events/1000 person-years among participants carrying one risk allele, and 11.64 events/1000 person-years among participants carrying two risk alleles (Table 2)”
> “Among participants with follow-up for ESRD events through 2008, 114 (3.7%) participants experienced an ESRD event over a median follow-up of 19.7 years.”

Source: [Foster et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3752955/)

<a id="topic-2.2.1.2.1-6"></a>

### Atherosclerosis Risk in Communities study: healthy middle-aged adults followed for 25 to 30 years

> “There were 5,075 Whites (86%), 701 Blacks carrying the low-risk APOL1 genotype (12%), and 110 Blacks carrying the high-risk APOL1 genotype (2%). The mean age at baseline was 53 ± 6 years.”
> “The odds of developing CKD stage 3a or worse were not different between low-risk and high-risk APOL1 group in both unadjusted and adjusted models (P = 0.26 and P = 0.39, respectively). At last follow-up, <5% developed ESKD, and 45% of individuals either died or reached ESKD with no difference in outcomes between the groups.”

Source: [Doshi et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11127222/)

<a id="topic-2.2.1.2.1-7"></a>

### Jackson Heart Study: incident albuminuria, CKD, and ESKD

> “Of 2,300 participants, 41.3% had zero, 45.1% had 1, and 13.6% had 2 APOL1 risk variants.”
> “Compared with participants with zero APOL1 risk variants, those with 2 alleles had an increased risk for incident albuminuria (adjusted HR [aHR], 1.88; 95% CI, 1.04 to 3.40), ESKD (aHR, 9.05; 95% CI, 1.79 to 45.85), incident CKD (aHR, 1.65; 95% CI, 1.06 to 2.57)”

Source: [Young et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8664705/)

<a id="topic-2.2.1.2.1-8"></a>

### CARDIA study: incident albuminuria in young adults

> “Mean age was 35 years, mean eGFRcys was 107 ml/min per 1.73 m2, and 13.2% of blacks had two APOL1 alleles. The incidence rate per 1000 person-years (95% confidence interval) for albuminuria over 15 years was 15.6 (10.6–22.1) for high-risk blacks, 7.8 (6.4–9.4) for low-risk blacks, and 3.9 (3.1–4.8) for whites. Compared with whites, the odds ratio (95% confidence interval) for incident albuminuria was 5.71 (3.64–8.94) for high-risk blacks and 2.32 (1.73–3.13) for low-risk blacks.”

Source: [Peralta et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4769203/)

<a id="topic-2.2.1.2.1-9"></a>

### United States, 2008 to 2018: incidence of FSGS-attributed kidney failure in the US Renal Data System

> “The mean annual period prevalence and incidence rates of FSGS-attributed kidney failure from 2008 to 2018 were 87.6 and 7.5 per million in the US population, respectively.”
> “The majority were White (61.8%) or Black (32.6%).”

Source: [Bensink et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10831785/)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
